Skip to main content
. 2022 Aug 24;12:957472. doi: 10.3389/fonc.2022.957472

Table 1.

Clinicopathological characteristics of uterine corpus endometrial carcinoma (UCEC) patients with differential RPP40 expression.

Characteristic Low-RPP40 expression (N = 276) High-RPP40 expression (N = 276) P-value
Clinical stage, n (%) 0.038
 Stage I 185 (33.5%) 157 (28.4%)
 Stage II 25 (4.5%) 26 (4.7%)
 Stage III 57 (10.3%) 73 (13.2%)
 Stage IV 9 (1.6%) 20 (3.6%)
Primary therapy outcome, n (%) < 0.001
 PD 8 (1.7%) 12 (2.5%)
 SD 3 (0.6%) 3 (0.6%)
 PR 0 (0%) 12 (2.5%)
 CR 238 (49.6%) 204 (42.5%)
Race, n (%) 0.176
 Asian 11 (2.2%) 9 (1.8%)
 Black or African American 45 (8.9%) 63 (12.4%)
 White 195 (38.5%) 184 (36.3%)
Age, n (%) 0.088
 <=60 113 (20.6%) 93 (16.9%)
 >60 161 (29.3%) 182 (33.2%)
BMI, n (%) 0.179
 <=30 99 (19.1%) 113 (21.8%)
 >30 163 (31.4%) 144 (27.7%)
Histological type, n (%) < 0.001
 Endometrioid 234 (42.4%) 176 (31.9%)
 Mixed 11 (2%) 13 (2.4%)
 Serous 31 (5.6%) 87 (15.8%)
Residual tumor, n (%) 0.857
 R0 193 (46.7%) 182 (44.1%)
 R1 10 (2.4%) 12 (2.9%)
 R2 8 (1.9%) 8 (1.9%)
Histologic grade, n (%) < 0.001
 G1 74 (13.7%) 24 (4.4%)
 G2 73 (13.5%) 47 (8.7%)
 G3 125 (23.1%) 198 (36.6%)
Tumor invasion (%), n (%) 0.697
 <50 134 (28.3%) 125 (26.4%)
 >=50 116 (24.5%) 99 (20.9%)
Menopause status, n (%) 0.500
 Pre 20 (4%) 15 (3%)
 Peri 10 (2%) 7 (1.4%)
 Post 223 (44.1%) 231 (45.7%)
Hormones therapy, n (%) 0.416
 No 148 (43%) 149 (43.3%)
 Yes 27 (7.8%) 20 (5.8%)
Diabetes, n (%) 0.403
 No 171 (37.9%) 157 (34.8%)
 Yes 58 (12.9%) 65 (14.4%)
Radiation therapy, n (%) 0.980
 No 142 (26.9%) 137 (26%)
 Yes 125 (23.7%) 123 (23.3%)
Surgical approach, n (%) 0.874
 Minimally invasive 103 (19.4%) 105 (19.8%)
 Open 163 (30.8%) 159 (30%)
OS event, n (%) < 0.001
 Alive 246 (44.6%) 212 (38.4%)
 Dead 30 (5.4%) 64 (11.6%)
DSS event, n (%) 0.003
 Alive 256 (46.5%) 231 (42%)
 Dead 20 (3.6%) 43 (7.8%)
PFI event, n (%) 0.005
 Alive 226 (40.9%) 197 (35.7%)
 Dead 50 (9.1%) 79 (14.3%)